The Letter of Intent signed by the Ministry of Health, the Latvian Academy of Sciences, the European Association of Pharmaceutical Industries and Associations (EFPIA) and the Association of International Research-based Pharmaceutical Manufacturers (SIFFA) on 29 June marks an important step forward in fostering the access to medicines and thus improving Latvian health outcomes.

The main goal of this Letter of Intent is to facilitate stable and predictable business conditions and access to innovative medicines and investments in research.

The Ministry of Health and the pharmaceutical industry agreed on the provision of transparency in the reimbursed medicines system, availability of medicines, result-oriented uptake of medicines, and the industry’s support to ensure the availability of medicines.

With a view to implementing these measures, the Ministry of Health and the pharmaceutical industry have agreed to establish a working group to develop specific proposals for this step-wise collaboration.

The Letter of Intent underscores the continued efforts of the research-based pharmaceutical industry to forge partnership with governments across Europe to support the sustainability of national health services and increase access to innovative medicines for the benefit of patients.